AngioDynamics Reports Improved Q2 FY26 Results, Reduces Net Loss, and Announces CEO Retirement
ANGO sits 31% above its 52-week low of $8.27.
Summary
AngioDynamics reported strong Q2 FY26 revenue growth and a reduced net loss, driven by its Med Tech segment, alongside the announcement of its CEO's planned retirement in late 2026.
Key Events · Earnings and Guidance · ANGO
-
Strong Revenue Growth
Net sales increased by 9.0% to $79.4 million for the three months ended November 30, 2025, and by 10.6% to $155.1 million for the six months, compared to the prior year periods. This growth was primarily driven by the Med Tech segment, which saw a 13.0% increase in Q2.
-
Reduced Net Loss
The company significantly reduced its net loss, reporting a loss of $6.4 million ($0.15 diluted loss per share) for Q2 FY26, an improvement from a $10.7 million loss ($0.26 diluted loss per share) in the same period last year.
-
Improved Gross Margin
Total company gross margin increased by 160 basis points to 56.4% in Q2 FY26, primarily due to higher sales volume, favorable product mix, and benefits from transitioning product lines to third-party manufacturers.
-
CEO Retirement Announced
James C. Clemmer, President and CEO, notified the Board of his intention to retire by November 30, 2026, or upon the appointment of a successor. A search committee has been formed to identify the next CEO.
Analysis · ANGO · Industrial Applications And Services
AngioDynamics' latest 10-Q filing indicates a positive trend in financial performance, with significant revenue growth and a reduced net loss compared to the prior year. The Med Tech segment, particularly Auryon and thrombus management products, is a key growth driver. While the company continues to operate at a net loss, the improvement in profitability metrics and cash flow from operations suggests a strengthening financial position. The announcement of the CEO's planned retirement in late 2026 introduces future leadership uncertainty, but the established search committee indicates a structured transition process. Investors should monitor the ongoing restructuring efforts and the CEO search for potential impacts.
At the time of this filing, ANGO was trading at $10.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $446.6M. The 52-week trading range was $8.27 to $13.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.